Replies to post #441260 on NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Thought I had found a bit of undiscovered info, oops.

But given this registry of glioblastoma patients, with IDH status, overall survival records, and with 274 patients in the population, I would think this 209 patients with wildtype IDH status can serve as a sufficiently large external control arm for our DCVax trial. Maybe that's all regulatory agencies need.

[flipper44]

Just set aside potential exclusion of idh mutant for the time being. Regarding IDH, the pertinent question is did (not will they) they match ECA idh status with the DCVax-l trial treatment and crossover idh status. We won’t know until we see the publication.